| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/03/2012 | CA2466054C Apo-2 ligand/trail formulations |
| 01/03/2012 | CA2463974C Dendrimers for use in targeted delivery |
| 01/03/2012 | CA2457863C Process for preparing glycopeptide phosphonate derivatives |
| 01/03/2012 | CA2436049C A serpin in bifidobacteria |
| 01/03/2012 | CA2431714C Oral composition providing enhanced tooth stain removal |
| 01/03/2012 | CA2425558C Lactam compound |
| 01/03/2012 | CA2420949C Peptide selection method |
| 01/03/2012 | CA2420618C Percarboxylated polysaccharides, and a process for their preparation |
| 01/03/2012 | CA2419954C Use of il-6r/il-6 chimera in huntington's disease |
| 01/03/2012 | CA2399505C Nasal calcitonin formulations |
| 01/03/2012 | CA2388180C Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 01/03/2012 | CA2362507C Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant |
| 01/03/2012 | CA2348698C Variants of humanized anti-carcinoma monoclonal antibody cc49 |
| 01/03/2012 | CA2347025C Zinc finger binding domains for gnn |
| 01/03/2012 | CA2334960C Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases |
| 01/03/2012 | CA2304952C Mannose-receptor bearing cells and antigen conjugate for immunotherapy |
| 01/03/2012 | CA2284000C Hydrophilic binary systems for the administration of cyclosporine |
| 01/03/2012 | CA2282719C A method for producing procollagen |
| 01/03/2012 | CA2266332C Antibodies against human parathyroid hormone related protein |
| 01/03/2012 | CA2264562C Sustained peptide-release formulation |
| 01/03/2012 | CA2258348C Screening compounds for the ability to alter the production of amyloid-.beta. peptide (x-.gtoreq.41) |
| 01/03/2012 | CA2242414C Anti-cd18 antibodies for use against stroke |
| 01/03/2012 | CA2236591C Continuous low-dose cytokine infusion therapy |
| 01/03/2012 | CA2229811C Inverted chimeric and hybrid oligonucleotides |
| 01/03/2012 | CA2227265C Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis |
| 01/03/2012 | CA2226973C Modulators of the function of fas receptors and other proteins |
| 01/03/2012 | CA2224468C P53 protein variants and therapeutical uses thereof |
| 01/03/2012 | CA2215483C Non-toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same |
| 01/03/2012 | CA2210998C Inhibition of neovascularization using vegf-specific oligonucleotides |
| 01/03/2012 | CA2209771C Combined therapeutical treatment of hyperproliferative diseases |
| 01/03/2012 | CA2178482C Thrombopoietin |
| 01/03/2012 | CA2171903C A substance or composition for use in a method of treatment of female mammals |
| 12/29/2011 | WO2011163669A2 Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
| 12/29/2011 | WO2011163652A2 Treatment of sanfilippo syndrome type b |
| 12/29/2011 | WO2011163651A2 METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE |
| 12/29/2011 | WO2011163650A2 Methods and compositions for cns delivery of arylsulfatase a |
| 12/29/2011 | WO2011163649A2 Methods and compositions for cns delivery of iduronate-2-sulfatase |
| 12/29/2011 | WO2011163648A1 Cns delivery of therapeutic agents |
| 12/29/2011 | WO2011163647A2 Methods and compositions for cns delivery of heparan n-sulfatase |
| 12/29/2011 | WO2011163637A2 Protein transduction domains mimics |
| 12/29/2011 | WO2011163572A2 Bifunctional conjugate compositions and associated methods |
| 12/29/2011 | WO2011163539A2 nAChRα7 AGONISTS AND nAChRα7 ANTAGONISTS FOR TREATING ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD) |
| 12/29/2011 | WO2011163531A2 Compositions and methods for re-programming cells without genetic modification for treatment of cardiovascular diseases |
| 12/29/2011 | WO2011163473A1 Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
| 12/29/2011 | WO2011163466A1 Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
| 12/29/2011 | WO2011163462A2 Amide-based insulin prodrugs |
| 12/29/2011 | WO2011163460A1 Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor |
| 12/29/2011 | WO2011163452A2 Treating surface of the eye disorders |
| 12/29/2011 | WO2011163398A2 Biomimetic peptides for bone augmentation |
| 12/29/2011 | WO2011163394A2 Compstatin analogs for treatment of neuropathic pain |
| 12/29/2011 | WO2011163312A2 Improving efficacy of cancer therapy |
| 12/29/2011 | WO2011163308A2 Compositions and methods for preventing and treating organ injury and/or dysfunction |
| 12/29/2011 | WO2011163301A1 Methods of treating optic disorders |
| 12/29/2011 | WO2011163206A2 Controlled release compositions with reduced food effect |
| 12/29/2011 | WO2011163069A2 Protease triggered release of molecules from hydrogels |
| 12/29/2011 | WO2011163012A2 Amide based glucagon superfamily peptide prodrugs |
| 12/29/2011 | WO2011162989A2 Glp-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| 12/29/2011 | WO2011162968A1 Dipeptide linked medicinal agents |
| 12/29/2011 | WO2011162831A2 Compositions and methods for treatment of thrombosis and prolonging survival of stored platelets |
| 12/29/2011 | WO2011162655A1 Compound and method for treatment of alzheimer's disease and familial dementia |
| 12/29/2011 | WO2011162558A2 Recombinant vector for suppressing proliferation of human papillomavirus cell including adenylate cyclase activating polypeptide 1 (pituitary) gene and pharmaceutical composition for treating human papillomavirus |
| 12/29/2011 | WO2011162419A1 Tumor growth controlling method targeting galactosylceramide expression factor-1 |
| 12/29/2011 | WO2011162413A1 Sustained-release formulation |
| 12/29/2011 | WO2011161531A1 Pharmaceutical composition containing goserelin for in-situ implant |
| 12/29/2011 | WO2011161491A1 Methods and pharmaceutical compositions for the treatment of respiratory tract infections |
| 12/29/2011 | WO2011161427A2 Glycoproteins having lipid mobilizing properties and therapeutic uses thereof |
| 12/29/2011 | WO2011161332A1 Novel octapeptide compounds and therapeutic use thereof |
| 12/29/2011 | WO2011161295A2 Use of anticalcineurin compounds for the treatment of pathologies involving ocular neovascularisation |
| 12/29/2011 | WO2011161217A2 Targeting of vegfr2 |
| 12/29/2011 | WO2011161165A1 Long-term storage of non-glycosylated recombinant human g-csf |
| 12/29/2011 | WO2011161161A1 Diabetes therapy |
| 12/29/2011 | WO2011161127A1 Protease variants of human neprilysin |
| 12/29/2011 | WO2011160845A2 Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment |
| 12/29/2011 | WO2011160826A1 Botulinum toxin therapy |
| 12/29/2011 | WO2011160823A1 Combination of d-amino acids and phenylbutyric acid |
| 12/29/2011 | WO2011160822A1 Organic salts and co-crystals of phenylbutyric acid of d-amino acids |
| 12/29/2011 | WO2011160732A1 Protease variants of human neprilysin |
| 12/29/2011 | WO2011160664A1 Treatment of vascular complications of diabetes |
| 12/29/2011 | WO2011160633A1 Glucagon analogues |
| 12/29/2011 | WO2011160563A1 Novel porcine interferon and use thereof |
| 12/29/2011 | WO2011160189A1 METHOD OF SCREENING FOR INHIBITORS OF sPLA2-IIA |
| 12/29/2011 | WO2011160184A1 Method of treatment |
| 12/29/2011 | WO2011160174A1 Treatment of proliferative diseases |
| 12/29/2011 | WO2011138785A3 Use of ccl1 in therapy |
| 12/29/2011 | WO2011133735A3 Uses of natriuretic peptide constructs |
| 12/29/2011 | WO2011131510A3 Selective modification of proteins |
| 12/29/2011 | WO2011128701A3 Cancer methods |
| 12/29/2011 | WO2011119833A3 Bmp-7 peptides & methods of use |
| 12/29/2011 | WO2011119738A9 Methods of treatment using stem cell mobilizers |
| 12/29/2011 | WO2011109729A9 Ep1 inhibition |
| 12/29/2011 | WO2011109511A3 Novel hiv-1 envelope glycoprotein |
| 12/29/2011 | WO2011103458A3 Compositions and methods for using and identifying antimicrobial agents |
| 12/29/2011 | WO2011103453A3 Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| 12/29/2011 | WO2011100508A3 Methods and compositions related to glycoprotein-immunoglobulin fusions |
| 12/29/2011 | WO2011100376A3 Methods and architecture for power optimization of iontophoretic transdermal drug delivery |
| 12/29/2011 | WO2011097573A3 Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells |
| 12/29/2011 | WO2011097571A3 Methods for the use of progestogen as a glucocorticoid sensitizer |
| 12/29/2011 | WO2011090947A3 Methods for the diagnosis and treatment of parkinson's disease |
| 12/29/2011 | WO2011072247A3 Pathogen restriction factors |
| 12/29/2011 | WO2011035013A3 Implant devices that differ by release profile and methods of making and using same |